vs
富兰克林柯维（FC）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是富兰克林柯维的1.1倍（$69.8M vs $64.0M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -5.1%，领先389.2%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -7.3%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 2.2%）
富兰克林柯维总部位于美国犹他州盐湖城，是一家专业培训指导企业，面向各类组织与个人提供领导力提升、个人效能成长与业务执行领域的培训及评估服务。公司由富兰克林奎斯特与柯维领导力中心于1997年合并成立，最为人熟知的产品包括富兰克林柯维规划系统等。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
FC vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.1倍
$64.0M
营收增速更快
RIGL
高出28.5%
-7.3%
净利率更高
RIGL
高出389.2%
-5.1%
两年增速更快
RIGL
近两年复合增速
2.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $64.0M | $69.8M |
| 净利润 | $-3.3M | $268.1M |
| 毛利率 | 75.5% | 91.5% |
| 营业利润率 | -5.7% | 33.2% |
| 净利率 | -5.1% | 384.0% |
| 营收同比 | -7.3% | 21.2% |
| 净利润同比 | -378.5% | 1769.2% |
| 每股收益（稀释后） | $-0.27 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCRIGL
| Q4 25 | $64.0M | $69.8M | ||
| Q3 25 | $71.2M | $69.5M | ||
| Q2 25 | $67.1M | $101.7M | ||
| Q1 25 | $59.6M | $53.3M | ||
| Q4 24 | $69.1M | $57.6M | ||
| Q3 24 | $84.1M | $55.3M | ||
| Q2 24 | $73.4M | $36.8M | ||
| Q1 24 | $61.3M | $29.5M |
净利润FCRIGL
| Q4 25 | $-3.3M | $268.1M | ||
| Q3 25 | $4.4M | $27.9M | ||
| Q2 25 | $-1.4M | $59.6M | ||
| Q1 25 | $-1.1M | $11.4M | ||
| Q4 24 | $1.2M | $14.3M | ||
| Q3 24 | $12.0M | $12.4M | ||
| Q2 24 | $5.7M | $-1.0M | ||
| Q1 24 | $874.0K | $-8.2M |
毛利率FCRIGL
| Q4 25 | 75.5% | 91.5% | ||
| Q3 25 | 75.5% | 93.2% | ||
| Q2 25 | 76.5% | 95.6% | ||
| Q1 25 | 76.7% | 91.7% | ||
| Q4 24 | 76.3% | 89.9% | ||
| Q3 24 | 78.1% | 85.5% | ||
| Q2 24 | 76.6% | 92.4% | ||
| Q1 24 | 76.4% | 93.1% |
营业利润率FCRIGL
| Q4 25 | -5.7% | 33.2% | ||
| Q3 25 | 11.1% | 40.9% | ||
| Q2 25 | -3.3% | 60.1% | ||
| Q1 25 | -2.4% | 23.9% | ||
| Q4 24 | 2.1% | 28.9% | ||
| Q3 24 | 21.3% | 25.4% | ||
| Q2 24 | 11.4% | 1.2% | ||
| Q1 24 | 2.4% | -23.6% |
净利率FCRIGL
| Q4 25 | -5.1% | 384.0% | ||
| Q3 25 | 6.1% | 40.2% | ||
| Q2 25 | -2.1% | 58.6% | ||
| Q1 25 | -1.8% | 21.5% | ||
| Q4 24 | 1.7% | 24.9% | ||
| Q3 24 | 14.2% | 22.5% | ||
| Q2 24 | 7.8% | -2.8% | ||
| Q1 24 | 1.4% | -27.9% |
每股收益（稀释后）FCRIGL
| Q4 25 | $-0.27 | $14.11 | ||
| Q3 25 | $0.34 | $1.46 | ||
| Q2 25 | $-0.11 | $3.28 | ||
| Q1 25 | $-0.08 | $0.63 | ||
| Q4 24 | $0.09 | $0.82 | ||
| Q3 24 | $0.89 | $0.70 | ||
| Q2 24 | $0.43 | $-0.06 | ||
| Q1 24 | $0.06 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $17.5M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $54.0M | $391.5M |
| 总资产 | $221.3M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资FCRIGL
| Q4 25 | $17.5M | $155.0M | ||
| Q3 25 | $31.7M | $137.1M | ||
| Q2 25 | $33.7M | $108.4M | ||
| Q1 25 | $40.4M | $77.1M | ||
| Q4 24 | $53.3M | $77.3M | ||
| Q3 24 | $48.7M | $61.1M | ||
| Q2 24 | $36.6M | $49.1M | ||
| Q1 24 | $40.9M | $49.5M |
总债务FCRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益FCRIGL
| Q4 25 | $54.0M | $391.5M | ||
| Q3 25 | $66.9M | $117.6M | ||
| Q2 25 | $65.6M | $81.9M | ||
| Q1 25 | $72.5M | $18.6M | ||
| Q4 24 | $80.6M | $3.3M | ||
| Q3 24 | $83.1M | $-14.6M | ||
| Q2 24 | $72.2M | $-29.9M | ||
| Q1 24 | $70.8M | $-31.7M |
总资产FCRIGL
| Q4 25 | $221.3M | $513.6M | ||
| Q3 25 | $242.9M | $242.5M | ||
| Q2 25 | $218.3M | $206.7M | ||
| Q1 25 | $221.3M | $176.0M | ||
| Q4 24 | $239.9M | $164.0M | ||
| Q3 24 | $261.5M | $139.4M | ||
| Q2 24 | $221.0M | $128.4M | ||
| Q1 24 | $221.9M | $126.5M |
负债/权益比FCRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $98.0K | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $-1.6M | — |
| 自由现金流率自由现金流/营收 | -2.5% | — |
| 资本支出强度资本支出/营收 | 2.7% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $5.9M | — |
8季度趋势，按日历期对齐
经营现金流FCRIGL
| Q4 25 | $98.0K | $22.0M | ||
| Q3 25 | $9.9M | $24.0M | ||
| Q2 25 | $6.3M | $30.5M | ||
| Q1 25 | $-1.4M | $-893.0K | ||
| Q4 24 | $14.1M | $14.5M | ||
| Q3 24 | $21.9M | $21.7M | ||
| Q2 24 | $8.2M | $302.0K | ||
| Q1 24 | $12.8M | $-5.0M |
自由现金流FCRIGL
| Q4 25 | $-1.6M | — | ||
| Q3 25 | $5.7M | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-2.6M | — | ||
| Q4 24 | $13.1M | — | ||
| Q3 24 | $20.8M | — | ||
| Q2 24 | $7.3M | — | ||
| Q1 24 | $12.1M | — |
自由现金流率FCRIGL
| Q4 25 | -2.5% | — | ||
| Q3 25 | 8.0% | — | ||
| Q2 25 | 6.7% | — | ||
| Q1 25 | -4.4% | — | ||
| Q4 24 | 19.0% | — | ||
| Q3 24 | 24.7% | — | ||
| Q2 24 | 9.9% | — | ||
| Q1 24 | 19.8% | — |
资本支出强度FCRIGL
| Q4 25 | 2.7% | — | ||
| Q3 25 | 5.9% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | 1.0% | — |
现金转化率FCRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | 2.27× | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | 11.98× | 1.01× | ||
| Q3 24 | 1.83× | 1.75× | ||
| Q2 24 | 1.43× | — | ||
| Q1 24 | 14.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
